Ranibizumab Treatment for Retinal Vein Occlusion

Predictive Factors of 2-year Visual Outcome in Retinal Vein Occlusion Following Intravitreal Ranibizumab Treatment

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01968616

Enrollment

100

Registered

2013-10-24

Start date

2013-09-30

Completion date

2019-09-30

Last updated

2017-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Edema Due to BRVO/CRVO

Brief summary

In retinal vein occlusion, predictive factors for visual outcome after ranibizumab treatment have not been evaluated comprehensively. Therefore, we have planned to analyze predictors for visual outcome from a viewpoint of electrophysiology and biomarkers besides morphological features by SD-OCT.

Interventions

DRUGRanibizumab, 0.5mg, Intravitreal

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Signed informed consent form * Male or female of aged 18 years or older * Macula edema secondary to BRVO/CRVO * Decrease of VA due to macular edema

Exclusion criteria

* Prior episode of RVO * Previous treatment with anti-VEGF drugs or corticosteroid or grid laser photocoagulation (study eye) * Ocular disorders in the study eye that may confound interpretation of study results * History of vitrectomy surgery, submacular surgery, or other surgical intervention for RVO * The pregnant or lactating woman

Design outcomes

Primary

Measure	Time frame
Mean foveal thickness measured by SD-OCT	2 years

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026